Skip to main content
. Author manuscript; available in PMC: 2014 Jul 24.
Published in final edited form as: Cancer Cell. 2013 May 16;23(6):839–852. doi: 10.1016/j.ccr.2013.04.008

Figure 1. EZH2 protein interacts with STAT3 in GSCs.

Figure 1

A and B) Co-immunoprecipitation (Co-IP) of EZH2 and STAT3 in GSCs (827 and 387). IgG represents a control antibody used for IPs. For IP-immunoblotting data, antibodies used for IP and Western blotting (WB) were labeled as red and blue, respectively. Two hundred μg of lysates were used for each IP reaction and total lysates (20 μg) were used as input controls. (C) Co-IP and immunoblot analysis of EZH2 and STAT3 in GSCs and NPCs vs. differentiated progenies. Differentiation was induced by culturing these cells in serum (10%)-containing media for three days. The EZH2-STAT3 complex was analyzed by co-IP, followed by immunoblot analysis. Protein levels of EZH2, SOX2 (a GSC-specific transcription factor), and GFAP (an astroglial differentiation marker) were examined. β-actin was used as a loading control. (D) Co-IP and immunoblots of the EZH2-STAT3 complexes in various cells. A 293T cell line (derived from human embryonic kidney cells) was used as a reference. See also Figure S1.